# US 2006/0040325 A1 · Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040325 A1
- Document ID: US20060040325A1
- Status: Published application
- Kind: A1
- Application number: 11/203,253
- Filed: 2005-08-15
- Published: 2006-02-23
- Earliest claimed: 2004-08-16
- Assignees: MedImmune, LLC
- Inventors: Herren Wu; Changshou Gao
- Web page: https://patentgrep.com/patent/US20060040325A1

## CPC

- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- G01N 33/575: for cancer
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to novel Fc variants of antibodies that immunospecifically binds to Integrin αvβ3. The Fc variants comprise a variable region that immunospecifically binds to Integrin αvβ3 and a Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants of an antibody that immunospecifically binds to Integrin αvβ3, particularly for therapeutic purposes.

## Claims

### Claim 1

An antibody that immunospecifically binds to Integrin αvβ3 comprising an IgG1 Fc region, wherein the Fc region comprises at least the high effector function amino acid residue 332E, as numbered by the EU index as set forth in Kabat, wherein the antibody comprising at least the high effector function amino acid residue 332E has an altered binding affinity for one or more FcγRs as compared to the same antibody not comprising at least the high effector function amino acid residue 332E.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the Fc region further comprises at least the high effector function amino acid residues 239D and 330L, as numbered by the EU index as set forth in Kabat.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the high effector function amino acid residue is selected from the group consisting of: 234E, 235R, 235A, 235W, 235P, 235V, 235Y, 236E, 239D, 265L, 269S, 269G, 2981, 298T, 298F, 327N, 327G, 327W, 328S, 328V, 329H, 329Q, 330K, 330V, 330G, 330Y, 330T, 330L, 330I, 330R, 330C, 332E, 332H, 332S, 332W, 332F, 332D, and 332Y, wherein the numbering system is that of the EU index as set forth in Kabat.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein said altered binding affinity for said one or more FcγRs is increased as compared to the same antibody not comprising at least the high effector function amino acid residue 332E.

### Claim 5 (depends on 4)

The antibody of claim 4, wherein said FcγR is FcγRIIIA.

### Claim 6 (depends on 4)

The antibody of claim 4, wherein said FcγR is FcγRIIB.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein said altered binding affinity for said one or more FcγRs is decreased as compared to the same antibody not comprising at least the high effector function amino acid residue 332E.

### Claim 8 (depends on 5)

The antibody of claim 5, wherein the equilibrium dissociation constant (KD) of binding for FcγRIIIA is decreased at least 2 fold as compared to the same antibody not comprising at least the high effector function amino acid residue 332E.

### Claim 9 (depends on 8)

The antibody of claim 8, wherein the equilibrium dissociation constant (KD) of binding for FcγRIIIA is decreased at least 70 fold as compared to the same antibody not comprising at least the high effector function amino acid residue 332E.

### Claim 10 (depends on 5)

The antibody of claim 5, wherein said increased affinity for FcγRIIIA results in an enhanced ADCC activity relative to a comparable molecule not comprising at least the high effector function amino acid residue 332E.

### Claim 11 (depends on 10)

The antibody of claim 10, wherein said enhanced ADCC activity is at least 2 fold greater relative to a comparable molecule not comprising at least the high effector function amino acid residue 332E.

### Claim 12 (depends on 1)

The antibody of claim 1, wherein said antibody is humanized, fully human, CDR-grafted, or chimeric.

### Claim 13 (depends on 12)

The antibody of claim 12, wherein said antibody is Vitaxin®.

### Claim 14 (depends on 12)

The antibody of claim 12, wherein said antibody variable sequences comprise SEQ ID Nos. 3 and 4.

### Claim 15 (depends on 12)

The antibody of claim 12, wherein said antibody is conjugated to a detectable agent, therapeutic agent or drug.

### Claim 16 (depends on 1)

A method of generating the antibody of claim 1, comprising (a) isolating antibody coding regions; and (b) making one or more desired substitutions in said Fc region of said isolated antibody coding region.

### Claim 17 (depends on 1)

A method of generating the antibody of claim 1, comprising subcloning variable regions into a vector encoding said Fc region comprising at least one or more high effector function amino acid residues.

### Claim 18 (depends on 1)

A formulation comprising a therapeutically effective amount of the antibody of claim 1 in a pharmaceutically-acceptable excipient.

### Claim 19 (depends on 18)

A method of ameliorating, treating or preventing cancer by administering the formulation of claim 18 to a patient in need thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein said cancer is of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, colorectal, stomach, spleen, renal, skeletal muscle, subcutaneous tissue, metastatic melanoma, endometrial, prostate, breast, ovaries, testicles, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain or central nervous system.

### Claim 21 (depends on 19)

The method of claim 19, wherein said administration is oral, parenteral, intramuscular, intranasal, vaginal, rectal, lingual, sublingual, buccal, intrabuccal, intravenous, cutaneous, subcutaneous or transdermal.

### Claim 22 (depends on 19)

The method of claim 19, further comprising administering said formulation in combination with other therapies, such as chemotherapy, hormonal therapy, biological therapy, immunotherapy or radiation therapy.
